FY2025 Earnings Forecast for CGTX Issued By Chardan Capital

Cognition Therapeutics, Inc. (NASDAQ:CGTX) – Equities research analysts at Chardan Capital issued their FY2025 EPS estimates for Cognition Therapeutics in a research report issued to clients and investors on Monday, March 24th. Chardan Capital analyst D. Gataulin expects that the company will earn ($0.32) per share for the year. Chardan Capital currently has a “Buy” rating and a $8.00 target price on the stock. The consensus estimate for Cognition Therapeutics’ current full-year earnings is ($0.80) per share. Chardan Capital also issued estimates for Cognition Therapeutics’ FY2026 earnings at ($0.15) EPS.

Cognition Therapeutics (NASDAQ:CGTX) last posted its quarterly earnings results on Thursday, March 20th. The company reported ($0.17) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.16) by ($0.01). During the same period in the previous year, the firm earned ($0.27) EPS.

A number of other analysts have also recently commented on the company. Brookline Capital Management upgraded Cognition Therapeutics to a “strong-buy” rating in a research report on Monday, January 27th. HC Wainwright lowered their price target on Cognition Therapeutics from $6.00 to $5.00 and set a “buy” rating for the company in a report on Monday, March 24th. Finally, B. Riley raised shares of Cognition Therapeutics from a “neutral” rating to a “buy” rating and upped their price objective for the company from $1.00 to $1.50 in a research note on Thursday, December 19th. One equities research analyst has rated the stock with a hold rating, four have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, Cognition Therapeutics presently has a consensus rating of “Buy” and an average target price of $7.13.

Cognition Therapeutics Stock Down 7.8 %

NASDAQ:CGTX opened at $0.42 on Thursday. The company has a market capitalization of $17.27 million, a PE ratio of -0.43 and a beta of 1.03. Cognition Therapeutics has a 52-week low of $0.34 and a 52-week high of $2.95. The stock has a fifty day simple moving average of $0.56 and a 200-day simple moving average of $0.54.

Institutional Investors Weigh In On Cognition Therapeutics

A number of institutional investors have recently added to or reduced their stakes in CGTX. BIOS Capital Management LP purchased a new position in shares of Cognition Therapeutics in the 4th quarter worth about $4,208,000. Voss Capital LP acquired a new stake in Cognition Therapeutics during the 4th quarter worth approximately $351,000. Sigma Planning Corp raised its holdings in Cognition Therapeutics by 211.6% in the fourth quarter. Sigma Planning Corp now owns 614,490 shares of the company’s stock valued at $431,000 after buying an additional 417,300 shares during the period. Virtu Financial LLC acquired a new position in Cognition Therapeutics during the third quarter valued at approximately $27,000. Finally, Two Sigma Investments LP grew its stake in Cognition Therapeutics by 372.2% during the fourth quarter. Two Sigma Investments LP now owns 53,691 shares of the company’s stock worth $38,000 after buying an additional 42,321 shares during the period. Hedge funds and other institutional investors own 43.35% of the company’s stock.

Cognition Therapeutics Company Profile

Cognition Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer's disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies.